EUVIMEDEUVIMED entdecken
Crossref

Treatment selection in the clinical practice of systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry

Masahiro Ayano iD, Naoyasu Ueda, Koji Mishima iD, Shun-Ichiro Ota, Kazuo Kushimoto, Atsushi Tanaka, Shotaro Kawano, Naoya Nishimura, Yusuke Kashiwado, Goro Doi, Tsuyoshi Nakayama, Ryo Fukumoto und 9 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Masahiro Ayano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Hydroxychloroquine, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Registries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to describe the treatment selection for systemic lupus erythematosus (SLE) using data from the Kyushu Collagen Disease Network for SLE (KCDN-SLE) registry, a multicentre prospective registry in Japan.

Methods

This study used data from patients registered between August 2022 and November 2023. Clinical characteristics, purpose of agent initiation, other candidate agents, and short-term efficacy and safety were evaluated.

Results

We analysed 69 previously treated patients with SLE (mean age 43.7 years; 62 females, 7 males). Hydroxychloroquine, biological agents, and immunosuppressive agents were initiated during the maintenance phase in 12, 41, and 16 patients, respectively. In patients with active organ involvement, hydroxychloroquine and biological agents were widely used for initiation. In those who already achieved treatment goals, biological agents alone were predominantly selected. The SLE Disease Activity Index 2000 score and prednisolone dose declined significantly over a 6-month follow-up period. Among 48 patients with active disease, 22 achieved a lupus low disease activity state, but this had no evident association with the initiation of a biological agent. In total, 14 adverse events, predominantly infections, were observed.

Conclusions

Biological agents were used preferentially, and the therapeutic agents were appropriately effective and mostly achieved the purpose of agent initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineImmunosuppressive AgentsLupus Erythematosus, SystemicRegistriesAdultFemaleHumansMaleMiddle AgedAntirheumatic AgentsJapanProspective StudiesSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Anifrolumabbelimumabbiological agentshydroxychloroquinesystemic lupus erythematosus

Substanzen

Antirheumatic AgentsHydroxychloroquineImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
  • Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Department of Rheumatology, Shimonoseki City Hospital, Shimonoseki, Japan.
  • Department of Rheumatology, Fukuoka Red Cross Hospital, Fukuoka, Japan.
  • Department of Rheumatology, Hamanomachi Hospital, Fukuoka, Japan.

ORCID-Profile: Masahiro Ayano, Koji Mishima, Makiko Maekawa, Koichi Akashi, Hiroaki Niiro

Zitieren

APA

Ayano, M., Ueda, N., Mishima, K., Ota, S. I., Kushimoto, K., Tanaka, A., Kawano, S., Nishimura, N., Kashiwado, Y., Doi, G., Nakayama, T., Fukumoto, R., Tsuru, T., Suzaki, M., Akahoshi, M., Maekawa, M., Omoto, A., Tada, H., Akashi, K., …, & Niiro, H. (2024). Treatment selection in the clinical practice of systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry. Modern Rheumatology. https://doi.org/10.1093/mr/roae058

Vancouver

Ayano M, Ueda N, Mishima K, Ota SI, Kushimoto K, Tanaka A, et al. Treatment selection in the clinical practice of systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry. Modern Rheumatology. 2024. doi:10.1093/mr/roae058

BibTeX
@article{Ayano2024,
  author = {Ayano, Masahiro and Ueda, Naoyasu and Mishima, Koji and Ota, Shun-Ichiro and Kushimoto, Kazuo and Tanaka, Atsushi and Kawano, Shotaro and Nishimura, Naoya and Kashiwado, Yusuke and Doi, Goro and Nakayama, Tsuyoshi and Fukumoto, Ryo and Tsuru, Tomomi and Suzaki, Midori and Akahoshi, Mitsuteru and Maekawa, Makiko and Omoto, Aya and Tada, Hitoshi and Akashi, Koichi and Horiuchi, Takahiko and Niiro, Hiroaki},
  title = {Treatment selection in the clinical practice of systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae058}
}
Kostenlos starten →